5-fluorouracil for Treatment of Stable Vitiligo

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-23

Study Completion Date

2024-04-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vitiligo, a significant dermatologic challenge affecting 0.5 to 2% of the global population. Despite various existing medical approaches, current vitiligo treatments are still far from optimal.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Topical 5-Fluorouracil Effervescent Powder in the Treatment of Vitiligo

NCT05536856

Vitiligo Topical Fluorouracil Effervescent Mixture

RECRUITING PHASE4

Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo.

NCT05513924

Vitiligo

COMPLETED PHASE2/PHASE3

Effect of Early Systemic Stabilization Therapy on Recent Onset Vitiligo

NCT05037981

Vitiligo

COMPLETED

Evaluation of Efficacy of Microneedling and Topical Methotrexate Versus Microneedling and Topical 5-flourouracil in Treatment of Vitillgo Patients

NCT05467839

Vitiligo

COMPLETED NA

Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo

NCT05008887

Vitiligo

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Vtiligo, a significant dermatologic challenge affecting 0.5 to 2% of the global population. Despite various existing medical approaches, current vitiligo treatments are still far from optimal. 5FU is a well-known chemotherapeutic agent that has been used for colorectal cancer treatment. The drug prevents DNA synthesis by inhibiting the thymidylate synthetase. The hyperpigmenta-tion of the skin is the most side effect observed with 5-FU therapy which directed its use in treat-ment of vitiligo. Besides, many studies reported that 5-FU could induce regimentation in vitiligo by direct stimulation of melanocytes and increasing melanosomes numbers in the keratinocytes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitiligo

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CO2 laser assisted dermabrasion and 5FU film

Group Type EXPERIMENTAL

5 fluorouracil

Intervention Type DRUG

5 fluorouracil (5FU) using different ratios of hydroxyl propyl methyl cellulose (HPMC) and Zein

CO2 laser assisted dermabrasion and saline

Group Type ACTIVE_COMPARATOR

Saline

Intervention Type OTHER

Normal saline solution contains 0.9 percent sodium chloride (salt)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

5 fluorouracil

5 fluorouracil (5FU) using different ratios of hydroxyl propyl methyl cellulose (HPMC) and Zein

Intervention Type DRUG

Saline

Normal saline solution contains 0.9 percent sodium chloride (salt)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with stable vitlligo

Exclusion Criteria

* patients under the age of 10 years.
* Individuals with a history of the Koebner phenomenon, a tendency for keloid or hypertrophic scarring
* Pregnancy.
* Recent isotretinoin therapy within the last 6 months.

Minimum Eligible Age

10 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes